| abstract |
The invention relates to therapeutic compositions and kits comprising: (i) at least two different Wnt antagonists or two polynucleotides each comprising a nucleotide sequence encoding a different Wnt antagonist (or vectors or cells containing said polynucleotides), or (ii) a first Wnt antagonist and a polynucleotide encoding a second Wnt antagonist. The invention also relates to the use of said compositions and kits for the treatment of cancer and, more specifically, for the treatment of diseases associated with unwanted angiogenesis. |